MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
24 Maio 2023 - 8:00AM
Business Wire
– Preclinical data in ASD model demonstrate
prosocial effects of MM-402 –
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED),
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, announced today the upcoming presentation of preclinical
data of MM-402, the Company’s proprietary form of the R-enantiomer
of 3,4-Methylenedioxymethamphetamine (“MDMA”), in a model for
autism spectrum disorder (“ASD”) at the ASCP 2023 Annual Meeting
that is being held in Miami Beach, FL from May 30-June 2, 2023. The
Company plans to initiate its first clinical trial of MM-402 in
2023.
The late-breaking poster entitled “MM-402,
R(−)-3,4-Methylenedioxymethamphetamine, Demonstrates Prosocial and
Therapeutic-Like Effects in Fmr1 Knockout Mice, a Preclinical Model
of Autism Spectrum Disorder (due to Fragile X syndrome),” will be
presented on Wednesday, May 31, 2023 at 11:15 am ET. This study
demonstrated that administration of MM-402 increased social
interaction in a characterized preclinical model of ASD. MM-402
exhibited a robust effect on social interaction and was more potent
than racemic MDMA with reduced hyperactivity effects.
“We are very pleased with these promising preclinical data,
which provide the first evidence of prosocial activity of MM-402 in
an ASD model and support the potential applications to enhancing
social functioning in individuals with ASD,” said Robert Barrow,
Chief Executive Officer and Director of MindMed. “Importantly,
MM-402 was able to achieve increased social interaction without the
level of hyperactivity seen with racemic MDMA. With even further
preclinical evidence to support our approach, we are extremely
excited to initiate our Phase 1 clinical trial of MM-402 later this
year.”
In addition to MindMed’s preclinical research program for
MM-402, MindMed’s collaborators at University Hospital Basel
(“UHB”) in Switzerland are currently enrolling participants in a
Phase 1 investigator-initiated trial of R-MDMA, S-MDMA and R/S-MDMA
in healthy volunteers. The Phase 1 trial is a randomized,
placebo-controlled, double-blind, 5-period crossover study. The
trial plans to enroll 24 healthy subjects, who will each receive
doses of R-MDMA (125 and 250 mg), S-MDMA (125 mg), MDMA (125 mg),
and placebo. Acute subjective effects in this study are being
assessed using the Visual Analog Scales (“VAS”) and the 5
Dimensions of Altered States of Consciousness (“5D-ASC”) along with
measurement of autonomic, endocrine and mood effects, among others.
Additional information about this trial is available on our website
(mindmed.co) and on clinicaltrials.gov (identifier:
NCT05277636).
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding anticipated
results and timing of clinical trials and the potential benefits of
the Company’s product candidates. There are numerous risks and
uncertainties that could cause actual results and the Company’s
plans and objectives to differ materially from those expressed in
the forward-looking information, including history of negative cash
flows; limited operating history; incurrence of future losses;
availability of additional capital; lack of product revenue;
compliance with laws and regulations; difficulty associated with
research and development; risks associated with clinical trials or
studies; heightened regulatory scrutiny; early stage product
development; clinical trial risks; regulatory approval processes;
novelty of the psychedelic inspired medicines industry; as well as
those risk factors discussed or referred to herein and the risks
described in the Company’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2022 and the Company’s Quarterly
Report on Form 10-Q for the fiscal quarter ended March 31, 2023
under headings such as “Special Note Regarding Forward-Looking
Statements,” and “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” and
other filings and furnishings made by the Company with the
securities regulatory authorities in all provinces and territories
of Canada which are available under the Company’s profile on SEDAR
at www.sedar.com and with the U.S. Securities and Exchange
Commission on EDGAR at www.sec.gov. Except as required by law, the
Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230524005326/en/
For Media & Investor Inquiries, please contact:
Maxim Jacobs, CFA Vice President, Investor Relations and
Corporate Communications Mind Medicine (MindMed) Inc. ir@mindmed.co
media@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024